• Je něco špatně v tomto záznamu ?

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

MA. Shah, T. Yoshino, NC. Tebbutt, A. Grothey, J. Tabernero, RH. Xu, A. Cervantes, SC. Oh, K. Yamaguchi, M. Fakih, A. Falcone, C. Wu, VK. Chiu, J. Tomasek, J. Bendell, M. Fontaine, M. Hitron, B. Xu, J. Taieb, E. Van Cutsem

. 2023 ; 22 (1) : 100-110. [pub] 20221111

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004017

PURPOSE: Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC. PATIENT AND METHODS: In the multi-center, open-label, phase III CanStem303C (NCT02753127) study, adults with histologically confirmed mCRC that progressed on first-line fluoropyrimidine plus oxaliplatin ± bevacizumab were randomized to twice-daily napabucasin plus FOLFIRI (napabucasin) or FOLFIRI alone (control). The primary endpoint was overall survival (OS) in the general study population and in patients with pSTAT3-positive tumors (biomarker-positive). RESULTS: In the general study population (napabucasin, n = 624; control, n = 629), median OS was 14.3 months for napabucasin and 13.8 months for control (hazard ratio [HR], 0.976, one-sided P = .74). Overall, 44% of patients were biomarker-positive (napabucasin, n = 275; control, n = 272). In the biomarker-positive population, median OS was 13.2 months for napabucasin and 12.1 months for control (HR, 0.969; one-sided P > .99). In the control arm, median OS was shorter for biomarker-positive versus biomarker negative patients (12.1 vs. 18.5 months; HR, 1.518; nominal 2-sided P = .0002). The most common treatment-emergent adverse events (TEAEs) were diarrhea (napabucasin, 84.6%; control, 53.9%), nausea (60.5%, 50.5%), vomiting (41.2%, 29.3%), and abdominal pain (41.0%, 25.2%). Grade ≥3 TEAEs occurred in 73.8% of napabucasin-treated and 66.7% of control-treated patients, most commonly diarrhea (21.2%, 7.0%), neutrophil count decreased (13.7%, 19.2%), and neutropenia (13.3%, 15.2%). Safety was similar in biomarker-positive patients. CONCLUSION: In patients with previously treated mCRC, adding napabucasin to FOLFIRI did not improve OS. Results from the control arm indicate that pSTAT3 is an adverse prognostic factor in mCRC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004017
003      
CZ-PrNML
005      
20230425141033.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clcc.2022.11.002 $2 doi
035    __
$a (PubMed)36503738
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Shah, Manish A $u Weill Cornell Medicine, New York, NY; New York-Presbyterian Hospital, New York, NY. Electronic address: mas9313@med.cornell.edu
245    10
$a Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study / $c MA. Shah, T. Yoshino, NC. Tebbutt, A. Grothey, J. Tabernero, RH. Xu, A. Cervantes, SC. Oh, K. Yamaguchi, M. Fakih, A. Falcone, C. Wu, VK. Chiu, J. Tomasek, J. Bendell, M. Fontaine, M. Hitron, B. Xu, J. Taieb, E. Van Cutsem
520    9_
$a PURPOSE: Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC. PATIENT AND METHODS: In the multi-center, open-label, phase III CanStem303C (NCT02753127) study, adults with histologically confirmed mCRC that progressed on first-line fluoropyrimidine plus oxaliplatin ± bevacizumab were randomized to twice-daily napabucasin plus FOLFIRI (napabucasin) or FOLFIRI alone (control). The primary endpoint was overall survival (OS) in the general study population and in patients with pSTAT3-positive tumors (biomarker-positive). RESULTS: In the general study population (napabucasin, n = 624; control, n = 629), median OS was 14.3 months for napabucasin and 13.8 months for control (hazard ratio [HR], 0.976, one-sided P = .74). Overall, 44% of patients were biomarker-positive (napabucasin, n = 275; control, n = 272). In the biomarker-positive population, median OS was 13.2 months for napabucasin and 12.1 months for control (HR, 0.969; one-sided P > .99). In the control arm, median OS was shorter for biomarker-positive versus biomarker negative patients (12.1 vs. 18.5 months; HR, 1.518; nominal 2-sided P = .0002). The most common treatment-emergent adverse events (TEAEs) were diarrhea (napabucasin, 84.6%; control, 53.9%), nausea (60.5%, 50.5%), vomiting (41.2%, 29.3%), and abdominal pain (41.0%, 25.2%). Grade ≥3 TEAEs occurred in 73.8% of napabucasin-treated and 66.7% of control-treated patients, most commonly diarrhea (21.2%, 7.0%), neutrophil count decreased (13.7%, 19.2%), and neutropenia (13.3%, 15.2%). Safety was similar in biomarker-positive patients. CONCLUSION: In patients with previously treated mCRC, adding napabucasin to FOLFIRI did not improve OS. Results from the control arm indicate that pSTAT3 is an adverse prognostic factor in mCRC.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a kolorektální nádory $x patologie $7 D015179
650    _2
$a kamptothecin $7 D002166
650    _2
$a fluoruracil $7 D005472
650    _2
$a leukovorin $7 D002955
650    _2
$a bevacizumab $7 D000068258
650    12
$a nádory tračníku $x chemicky indukované $7 D003110
650    12
$a nádory rekta $7 D012004
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yoshino, Takayuki $u National Cancer Center Hospital East (NCCE), Kashiwa, Japan
700    1_
$a Tebbutt, Niall C $u Department of Medical Oncology, Austin Health, Melbourne, Australia; University of Melbourne, Melbourne, Australia
700    1_
$a Grothey, Axel $u West Cancer Center and Research Institute, Germantown, TN
700    1_
$a Tabernero, Josep $u Vall d'Hebron Hospital, Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic- UCC, Barcelona, Spain
700    1_
$a Xu, Rui-Hua $u Sun Yat-sen University Cancer Center, Guangzhou, China
700    1_
$a Cervantes, Andres $u Incliva Biomedical Research Institute, Valencia, Spain; University of Valencia, Valencia, Spain
700    1_
$a Oh, Sang Cheul $u Korea University College of Medicine, Seoul, South Korea
700    1_
$a Yamaguchi, Kensei $u Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
700    1_
$a Fakih, Marwan $u City of Hope Comprehensive Cancer Center, Duarte, CA
700    1_
$a Falcone, Alfredo $u University of Pisa, Pisa, Italy; Department of Translational Research, University of Pisa, Pisa, Italy
700    1_
$a Wu, Christina $u Winship Cancer Institute, Emory University, Atlanta, GA
700    1_
$a Chiu, Vi K $u The Angeles Clinic & Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA
700    1_
$a Tomasek, Jiri $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Bendell, Johanna $u Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
700    1_
$a Fontaine, Marilyn $u Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA
700    1_
$a Hitron, Matthew $u Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA
700    1_
$a Xu, Bo $u Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA
700    1_
$a Taieb, Julien $u Hôpital Europeen Georges Pompidou, APHP, Paris, France; Université de Paris, Paris, France; CARPEM Cancer Institute, Paris, France
700    1_
$a Van Cutsem, Eric $u University Hospitals Gasthuisberg, Leuven & KULeuven, Leuven, Belgium
773    0_
$w MED00007435 $t Clinical colorectal cancer $x 1938-0674 $g Roč. 22, č. 1 (2023), s. 100-110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36503738 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141030 $b ABA008
999    __
$a ok $b bmc $g 1924584 $s 1190226
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 22 $c 1 $d 100-110 $e 20221111 $i 1938-0674 $m Clinical colorectal cancer $n Clin Colorectal Cancer $x MED00007435
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace